基于AA-2024修订标准验证淀粉样蛋白级联假说
结果显示仅约31%至36%的受试者符合级联预测,提示AD连续谱中病理与临床症状的耦合存在显著异质性。
要点
- 仅约三分之一AA-2024诊断的AD患者符合淀粉样蛋白级联假说预测。
- 联合病理与认知韧性比例随tau-PET截断值方法大幅波动。
- 结果提示抗淀粉样蛋白试验解读与未来研究设计需考虑异质性。
核心结论
- 仅约三分之一符合AA-2024 AD诊断者遵循淀粉样蛋白级联假说预测,提示临床与病理耦合存在异质性。
研究设计与样本
- 采用改编自AA-2024标准的4×4生物学/临床分期矩阵,生物学分期由淀粉样蛋白与tau-PET负荷定义。
- tau-PET截断值通过5种不同方法确定,并将参与者分为符合级联、韧性与联合病理三类。
主要发现
- 符合淀粉样蛋白级联的比例在31%(95%CI 25%-37%)至36%(95%CI 30%-42%)之间,取决于tau-PET截断值方法。
- 符合级联人数高于零穿透情景但低于高穿透分布(p<0.01)。
- 联合病理比例为17%-63%,韧性比例为6%-52%,随tau-PET截断值方法差异显著(p<0.001)。
关键数值与推荐
- 生物学分期:A期为淀粉样蛋白阳性(A+),B期为内侧颞叶tau(A+/T2MTL+),C期为中度新皮层tau(A+/T2MOD+),D期为高度新皮层tau(A+/T2HIGH+)。
- 临床分期:1期为认知正常,2期为细微认知障碍,3期为轻度认知障碍,4-6期为痴呆。
临床怎么用
- 解读抗淀粉样蛋白临床试验结果时需考虑仅约三分之一患者符合级联预测。
- 未来AD研究设计应纳入生物学与临床分期不匹配的异质性人群。
局限性
- 横断面设计无法验证随时间推移的级联进程。
- tau-PET截断值方法的选择显著影响分类比例,结果稳健性受限。
- 样本来自ADNI队列,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The amyloid cascade hypothesis posits that Alzheimer disease (AD) progresses from amyloid deposition to tau deposition, neurodegeneration, and eventually cognitive impairment and is the foundation of the revised criteria of Alzheimer's Association Workgroup 2024 (AA-2024). To account for copathologies and cognitive resilience that affect the penetrance of the AD cascade, AA-2024 introduced a 2-dimensional biological-clinical staging framework. We aimed to estimate the proportion of persons along the AD continuum whose biological and clinical trajectories align with the amyloid cascade. METHODS: Cross-sectional data of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort were tested in the 4 × 4 biological/clinical staging matrix adapted from the AA-2024 criteria. Biological stages were defined by amyloid and tau-PET burden: stage A (amyloid positivity, A+), stage B (medial temporal tau, A+/T2MTL+), stage C (moderate neocortical tau, A+/T2MOD+), and stage D (high neocortical tau, A+/T2HIGH+). Clinical stages were cognitively unimpaired (stage 1), subtle cognitive impairment (stage 2), mild cognitive impairment (stage 3), and dementia (stages 4-6). Tau-PET cutoffs were defined through the implementation of 5 distinct methods. Participants were categorized into (1) compliant with the amyloid cascade (matrix diagonal), (2) resilient (advanced biological stage-early clinical stage), and (3) copathologic (early biological stage-advanced clinical stage). Observed distributions were compared with hypothetical scenarios with zero and high amyloid cascade penetrance using the χ2 test, and differences among the 5 methods were tested using the Cochran Q test. RESULTS: Two-hundred and fifty-six amyloid-positive individuals (mean age: 72.7 years; 51% female) from the ADNI cohort were considered. The proportion of participants compliant with the amyloid cascade was between 31% (95% CI 25%-37%) and 36% (95% CI 30%-42%) depending on the tau-PET cutoff method. The observed number of individuals compliant with the amyloid cascade was higher than in the zero-penetrance scenario but lower than in the high-penetrance distribution (p < 0.01). The proportion of copathologic (17%-63%) and resilient (6%-52%) individuals varied widely by tau-PET cutoff (p < 0.001). DISCUSSION: Only approximately one-third of persons with an AA-2024 diagnosis of AD complied with the predictions of the amyloid cascade hypothesis. These results suggest the heterogeneity in how clinical symptoms and pathology are coupled along the AD continuum, which has significant implications for interpreting completed antiamyloid clinical trials and designing future studies.
引用
- Mendes AJ, Ribaldi F, Pievani M, et al. Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease. Neurology. 2025. PMID: 40359457. doi:10.1212/WNL.0000000000213675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。